Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 500 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR “Supporting research is mission critical for me and always will be”... November 29, 2021 In Memory of Håkan Mellstedt: Former ESMO President August 26, 2025 Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic... July 2, 2021 ¿Comer alimentos a la parrilla o asados puede provocar cáncer? September 14, 2023 Load more HOT NEWS New Blood Test Can Screen For Over 50 Cancers 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected... Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs... Favourable Benefit-Risk Profile of Trastuzumab Deruxtecan in Patients with HER2-positive MBC...
